MEDG Medgenics(Regs)

 

TIDMMEDG 
 
RNS Number : 7686S 
Medgenics Inc 
15 September 2010 
 

 
 
                                Medgenics, Inc. 
                         ('Medgenics' or the 'Company') 
 
                              Fund raising update 
15 September 2010 
 
Medgenics, Inc. (AIM: MEDG, MEDU), the company that has developed a novel 
technology for the manufacture and delivery of therapeutic proteins continuously 
in patients using their own tissue, announces that, further to the announcement 
dated 24 August 2010 it has not yet closed its sale of new convertible 
debentures and has decided to extend the closing date of this debenture issue 
until the end of September 2010. The Directors are confident that the debenture 
round will close successfully and the Company will announce the result of the 
debenture round at such time. 
 
For further information, contact: 
 
+--------------------------------------+------------------------+ 
| Medgenics, Inc.                      | Phone: +972 4 902 8900 | 
| Dr. Andrew L. Pearlman               |                        | 
|                                      |                        | 
+--------------------------------------+------------------------+ 
| Religare Capital Markets (Nominated  | Phone: +44 207 444     | 
| Adviser)                             | 0800                   | 
| James Pinner                         |                        | 
| Derek Crowhurst                      |                        | 
|                                      |                        | 
+--------------------------------------+------------------------+ 
| SVS Securities plc (Joint Broker)    | Phone: +44 207 638     | 
| Ian Callaway                         | 5600                   | 
|                                      |                        | 
+--------------------------------------+------------------------+ 
| Nomura Code Securities PLC (Joint    | Phone: +44 207 776     | 
| Broker)                              | 1219                   | 
| Jon Senior                           |                        | 
|                                      |                        | 
+--------------------------------------+------------------------+ 
| De Facto Communications              | Phone: +44 20 7861     | 
| Mike Wort                            | 3838                   | 
| Anna Dunphy                          |                        | 
|                                      |                        | 
+--------------------------------------+------------------------+ 
| Grayling (Investment Relations - US) | Phone:  +1 646 284     | 
| Leslie Wolf-Creutzfeldt              | 9472                   | 
+--------------------------------------+------------------------+ 
Notes to Editors: 
About Medgenics: 
Medgenics is a commercial-stage biopharmaceutical company developing its unique 
tissue-based Biopump platform technology to provide sustained-action protein 
therapy for the treatment of a range of chronic diseases. The first revenue 
generating commercial deal with a well-known multinational pharmaceutical 
company was negotiated in late 2009 and we look forward to generating additional 
deals to further commercialise the Biopump platform technology. 
For more information please visit: www.medgenics.com 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCUVVSRRUAKAAR 
 

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024